Next Article in Journal
Study of the Genetic Variants in BRCA1/2 and Non-BRCA Genes in a Population-Based Cohort of 2155 Breast/Ovary Cancer Patients, Including 443 Triple-Negative Breast Cancer Patients, in Argentina
Next Article in Special Issue
Transcript-Level Dysregulation of BCL2 Family Genes in Acute Myeloblastic Leukemia
Previous Article in Journal
Ubiquitin Specific Protease 29 Functions as an Oncogene Promoting Tumorigenesis in Colorectal Carcinoma
Previous Article in Special Issue
Impact of Mantle Cell Lymphoma Contamination of Autologous Stem Cell Grafts on Outcome after High-Dose Chemotherapy
Review

Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review

1
Department of Pathology, Keio University, School of Medicine, Tokyo 160-8582, Japan
2
Division of Hematology, Department of Internal of Medicine, Keio University, School of Medicine, Tokyo 160-8582, Japan
Academic Editors: Nicola Stefano Fracchiolla and Francesco Onida
Cancers 2021, 13(11), 2712; https://doi.org/10.3390/cancers13112712
Received: 30 December 2020 / Revised: 22 February 2021 / Accepted: 1 March 2021 / Published: 31 May 2021
(This article belongs to the Special Issue Hematologic Malignancy)
Despite rapid advances in the development of novel agents over the last decade for the treatment of multiple myeloma (MM), MM remains an incurable disease. Therefore, the development of novel targeting therapies with different mechanisms of action is needed to achieve a deep and durable response for the cure of MM. Recently, an antibody-drug conjugate (ADC), belanatmab mafadotin, which targets B cell membrane antigen (BCMA) on plasma cells, was approved for the treatment of relapsed or refractory MM in 2020. To date, immunotherapies including bi-specific or tri-specific antibodies, adoptive cellular therapy using autologous chimeric antigen (CAR)-T cells, allogeneic CAR-natural killer (NK) cells, and checkpoint inhibitors have been developed for MM, and a variety of clinical trials are currently underway or planned. This review presents an update on the most recent clinical and preclinical advances with a focus on results from clinical trials in progress with BCMA-targeted immunotherapies or the development of other novel targets in MM.
Despite rapid advances in treatment approaches of multiple myeloma (MM) over the last two decades via proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and monoclonal antibodies (mAbs), their efficacies are limited. MM still remains incurable, and the majority of patients shortly relapse and eventually become refractory to existing therapies due to the genetic heterogeneity and clonal evolution. Therefore, the development of novel therapeutic strategies with different mechanisms of action represents an unmet need to achieve a deep and highly durable response as well as to improve patient outcomes. The antibody-drug conjugate (ADC), belanatmab mafadotin, which targets B cell membrane antigen (BCMA) on plasma cells, was approved for the treatment of MM in 2020. To date, numerous immunotherapies, including bispecific antibodies, such as bispecific T cell engager (BiTE), the duobody adoptive cellular therapy using a dendritic cell (DC) vaccine, autologous chimeric antigen (CAR)-T cells, allogeneic CAR-natural killer (NK) cells, and checkpoint inhibitors have been developed for the treatment of MM, and a variety of clinical trials are currently underway or are expected to be planned. In the future, the efficacy of combination approaches, as well as allogenic CAR-T or NK cell therapy, will be examined, and promising results may alter the treatment paradigm of MM. This is a comprehensive review with an update on the most recent clinical and preclinical advances with a focus on results from clinical trials in progress with BCMA-targeted immunotherapies and the development of other novel targets in MM. Future perspectives will also be discussed. View Full-Text
Keywords: multiple myeloma; belanatmab mafadotin; ADC; BCMA; immunotherapies; bispecific antibody; BiTE; autologous CAR-T cell; allogenic CAR-NK cell multiple myeloma; belanatmab mafadotin; ADC; BCMA; immunotherapies; bispecific antibody; BiTE; autologous CAR-T cell; allogenic CAR-NK cell
Show Figures

Figure 1

MDPI and ACS Style

Nishida, H. Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review. Cancers 2021, 13, 2712. https://doi.org/10.3390/cancers13112712

AMA Style

Nishida H. Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review. Cancers. 2021; 13(11):2712. https://doi.org/10.3390/cancers13112712

Chicago/Turabian Style

Nishida, Hiroko. 2021. "Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review" Cancers 13, no. 11: 2712. https://doi.org/10.3390/cancers13112712

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop